Literature DB >> 27013075

Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications.

Philippe De Deurwaerdère1, Giuseppe Di Giovanni2.   

Abstract

Since their discovery in the mammalian brain, it has been apparent that serotonin (5-HT) and dopamine (DA) interactions play a key role in normal and abnormal behavior. Therefore, disclosure of this interaction could reveal important insights into the pathogenesis of various neuropsychiatric diseases including schizophrenia, depression and drug addiction or neurological conditions such as Parkinson's disease and Tourette's syndrome. Unfortunately, this interaction remains difficult to study for many reasons, including the rich and widespread innervations of 5-HT and DA in the brain, the plethora of 5-HT receptors and the release of co-transmitters by 5-HT and DA neurons. The purpose of this review is to present electrophysiological and biochemical data showing that endogenous 5-HT and pharmacological 5-HT ligands modify the mesencephalic DA systems' activity. 5-HT receptors may control DA neuron activity in a state-dependent and region-dependent manner. 5-HT controls the activity of DA neurons in a phasic and excitatory manner, except for the control exerted by 5-HT2C receptors which appears to also be tonically and/or constitutively inhibitory. The functional interaction between the two monoamines will also be discussed in view of the mechanism of action of antidepressants, antipsychotics, anti-Parkinsonians and drugs of abuse.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressant; Antipsychotic; Drug abuse; Electrophysiology; Microdialysis; Serotonin receptors

Mesh:

Substances:

Year:  2016        PMID: 27013075     DOI: 10.1016/j.pneurobio.2016.03.004

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  41 in total

1.  Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens.

Authors:  Yuki Asari; Yumiko Ikeda; Amane Tateno; Yoshiro Okubo; Takehiko Iijima; Hidenori Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2018-06-27       Impact factor: 4.530

2.  Updating neuropathology and neuropharmacology of monoaminergic systems.

Authors:  Rona R Ramsay; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  Br J Pharmacol       Date:  2016-07       Impact factor: 8.739

3.  An Interaction between Serotonin Receptor Signaling and Dopamine Enhances Goal-Directed Vigor and Persistence in Mice.

Authors:  Matthew R Bailey; Olivia Goldman; Estefanía P Bello; Muhammad O Chohan; Nuri Jeong; Vanessa Winiger; Eileen Chun; Elke Schipani; Abigail Kalmbach; Joseph F Cheer; Peter D Balsam; Eleanor H Simpson
Journal:  J Neurosci       Date:  2018-01-24       Impact factor: 6.167

4.  p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease.

Authors:  John P Kostrzewa; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2020-01-14       Impact factor: 3.911

Review 5.  Do your gut microbes affect your brain dopamine?

Authors:  Camila González-Arancibia; Jocelyn Urrutia-Piñones; Javiera Illanes-González; Jonathan Martinez-Pinto; Ramón Sotomayor-Zárate; Marcela Julio-Pieper; Javier A Bravo
Journal:  Psychopharmacology (Berl)       Date:  2019-05-17       Impact factor: 4.530

6.  MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Authors:  Eduard R Mingazov; Gulnara R Khakimova; Elena A Kozina; Alexei E Medvedev; Olga A Buneeva; Ara S Bazyan; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

7.  The 5-HT1B serotonin receptor regulates methylphenidate-induced gene expression in the striatum: Differential effects on immediate-early genes.

Authors:  David Alter; Joel A Beverley; Ronak Patel; Carlos A Bolaños-Guzmán; Heinz Steiner
Journal:  J Psychopharmacol       Date:  2017-07-18       Impact factor: 4.153

8.  Pharmacological Modulation of 5-HT2C Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice.

Authors:  Caleb J Browne; Xiaodong Ji; Guy A Higgins; Paul J Fletcher; Colin Harvey-Lewis
Journal:  Neuropsychopharmacology       Date:  2017-06-13       Impact factor: 7.853

9.  Inter-individual differences in the impulsive/compulsive dimension: deciphering related dopaminergic and serotonergic metabolisms at rest.

Authors:  Françoise Dellu-Hagedorn; Marion Rivalan; Aurélie Fitoussi; Philippe De Deurwaerdère
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-04-19       Impact factor: 6.237

10.  Preferential modulation of the lateral habenula activity by serotonin-2A rather than -2C receptors: Electrophysiological and neuroanatomical evidence.

Authors:  Francis Delicata; Cristiano Bombardi; Massimo Pierucci; Roberto Di Maio; Philippe De Deurwaerdère; Giuseppe Di Giovanni
Journal:  CNS Neurosci Ther       Date:  2018-02-25       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.